Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial

摘要: BACKGROUND We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) its major binding protein (insulin-like 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS We conducted a nested-case–control study the placebo arm cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two more IPSS scores >14; at least five points over baseline one which was ≥12. Controls frequency matched by age to cases, reported no BPH treatment, score >8. controls remained on PCPT followed closely until their 7-year anniversary. Baseline serum analyzed IGFI IGFBP3. Unconditional logistic regression polytomous estimated multivariate-adjusted odds ratio (OR) risk. RESULTS IGFBP3 inversely IGFI:IGFBP3 positively associated risk, but findings statistically significant only severe symptoms (OR = 0.60, 95% CI = 0.40–0.90 fifth vs. first quintile IGFBP3, P-trend = 0.01). Associations did not differ (<65 ≥65 years), there suggestion that – association may be stronger among overweight men. CONCLUSIONS A high increased IGFBP3 decreased symptoms. These results confirm from other recent studies. Prostate 68: 1477–1486, 2008. © 2008 Wiley-Liss, Inc.